BUZZ-Sionna Therapeutics set to open 50% above offer price after upsized $191 mln IPO

Updates

Shares of drug developer Sionna Therapeutics SION.O set to open 50% above their offer price in their Nasdaq debut

Stock indicated to open at $27 vs $18 IPO price

SION sold ~10.6 mln shares, 20% more than initially offered, at the top end of its marketed range of $16 to $18 apiece to raise $190.6 mln

At the IPO price, the Waltham, Massachusetts-based firm fetched a valuation of $765.4 mln

Founded in 2019 and previously known as Sling Therapeutics, SION is developing drugs to treat cystic fibrosis

SION is vying for a slice of the cystic fibrosis market that is dominated by drugmaker Vertex Pharmaceuticals VRTX.O

Vertex booked almost $10 billion in sales in 2023 and has significantly impacted cystic fibrosis treatment

*SION is evaluating its experimental drug candidates SION-719 and SION-451 in early-stage trials in Australia

Prior to the IPO, SION had raised about $330 mln from investors, including RA Capital, TPG's Rise Fund, and Atlas Venture

Goldman Sachs, TD Cowen, Stifel and Guggenheim Securities were the underwriters